tetano
Editor, Senior Moderator
Viruses. 2017 Aug 8;9(8). pii: E209. doi: 10.3390/v9080209.
[h=1]Characterization of Monoclonal Antibodies against HA Protein of H1N1 Swine Influenza Virus and Protective Efficacy against H1 Viruses in Mice.[/h] Liu Y[SUP]1[/SUP], Li H[SUP]2[/SUP], Xue Y[SUP]3[/SUP], Zhao S[SUP]4[/SUP], Li C[SUP]5[/SUP], Qu L[SUP]6[/SUP], Zhang Y[SUP]7[/SUP], Liu M[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H1N1 swine influenza viruses (SIV) are prevalent in pigs globally, and occasionally emerge in humans, which raises concern about their pandemic threats. To stimulate hemagglutination (HA) of A/Swine/Guangdong/LM/2004 (H1N1) (SW/GD/04) antibody response, eukaryotic expression plasmid pCI-neo-HA was constructed and used as an immunogen to prepare monoclonal antibodies (mAbs). Five mAbs (designed 8C4, 8C6, 9D6, 8A4, and 8B1) against HA protein were obtained and characterized. Western blot showed that the 70 kDa HA protein could be detected by all mAbs in MDCK cells infected with SW/GD/04. Three mAbs-8C4, 8C6, and 9D6-have hemagglutination inhibition (HI) and neutralization test (NT) activities, and 8C6 induces the highest HI and NT titers. The protection efficacy of 8C6 was investigated in BALB/c mice challenged with homologous or heterologous strains of the H1 subtype SIV. The results indicate that mAb 8C6 protected the mice from viral infections, especially the homologous strain, which was clearly demonstrated by the body weight changes and reduction of viral load. Thus, our findings document for the first time that mAb 8C6 might be of potential therapeutic value for H1 subtype SIV infection.
[h=4]KEYWORDS:[/h] HA protein; monoclonal antibodies; protection efficacy; swine influenza virus
PMID: 28786930 DOI: 10.3390/v9080209
Free full text
[h=1]Characterization of Monoclonal Antibodies against HA Protein of H1N1 Swine Influenza Virus and Protective Efficacy against H1 Viruses in Mice.[/h] Liu Y[SUP]1[/SUP], Li H[SUP]2[/SUP], Xue Y[SUP]3[/SUP], Zhao S[SUP]4[/SUP], Li C[SUP]5[/SUP], Qu L[SUP]6[/SUP], Zhang Y[SUP]7[/SUP], Liu M[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H1N1 swine influenza viruses (SIV) are prevalent in pigs globally, and occasionally emerge in humans, which raises concern about their pandemic threats. To stimulate hemagglutination (HA) of A/Swine/Guangdong/LM/2004 (H1N1) (SW/GD/04) antibody response, eukaryotic expression plasmid pCI-neo-HA was constructed and used as an immunogen to prepare monoclonal antibodies (mAbs). Five mAbs (designed 8C4, 8C6, 9D6, 8A4, and 8B1) against HA protein were obtained and characterized. Western blot showed that the 70 kDa HA protein could be detected by all mAbs in MDCK cells infected with SW/GD/04. Three mAbs-8C4, 8C6, and 9D6-have hemagglutination inhibition (HI) and neutralization test (NT) activities, and 8C6 induces the highest HI and NT titers. The protection efficacy of 8C6 was investigated in BALB/c mice challenged with homologous or heterologous strains of the H1 subtype SIV. The results indicate that mAb 8C6 protected the mice from viral infections, especially the homologous strain, which was clearly demonstrated by the body weight changes and reduction of viral load. Thus, our findings document for the first time that mAb 8C6 might be of potential therapeutic value for H1 subtype SIV infection.
[h=4]KEYWORDS:[/h] HA protein; monoclonal antibodies; protection efficacy; swine influenza virus
PMID: 28786930 DOI: 10.3390/v9080209
Free full text